Table 1.
Baseline characteristics of patients with baseline EQ-5D scores in the FAS
| Characteristic | GEM (n=244) |
S-1 (n=245) |
GS (n=247) |
|||
| n | % | n | % | n | % | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 153 | 62.7 | 148 | 60.4 | 145 | 58.7 |
| Female | 91 | 37.3 | 97 | 39.6 | 102 | 41.3 |
| Age, years | ||||||
| <65 | 119 | 48.8 | 119 | 48.6 | 125 | 50.6 |
| ≥65 | 125 | 51.2 | 126 | 51.4 | 122 | 49.4 |
| ECOG PS | ||||||
| 0 | 156 | 63.9 | 148 | 60.4 | 155 | 62.8 |
| 1 | 88 | 36.1 | 97 | 39.6 | 92 | 37.2 |
| Extent of disease | ||||||
| Locally advanced | 53 | 21.7 | 58 | 23.7 | 57 | 23.1 |
| Metastatic | 191 | 78.3 | 187 | 76.3 | 190 | 76.9 |
| Type of tumour | ||||||
| Adenocarcinoma | 240 | 98.4 | 241 | 98.4 | 244 | 98.8 |
| Adenosquamous carcinoma |
4 | 1.6 | 4 | 1.6 | 3 | 1.2 |
| Pancreatic excision | ||||||
| No | 222 | 91.0 | 231 | 94.3 | 221 | 89.5 |
| Yes | 22 | 9.0 | 14 | 5.7 | 26 | 10.5 |
| Tumour location* | ||||||
| Head | 108 | 44.3 | 91 | 37.1 | 102 | 41.3 |
| Body | 76 | 31.1 | 109 | 44.5 | 88 | 35.6 |
| Tail | 61 | 25.0 | 50 | 20.4 | 61 | 24.7 |
*Including patients with tumours involving multiple sites.
ECOG PS, Eastern Cooperative Oncology Group performance status; EQ-5D, EuroQol-5D-3L; FAS, full analysis set; GEM, gemcitabine; GS, gemcitabine plus S-1.